Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have made significant strides in the fight against acute promyelocytic leukemia (APL) by developing an oral formulation of arsenic trioxide, known as ARSENOL®. This groundbreaking product marks a major milestone, as it is the first prescription medication entirely invented and manufactured in Hong Kong, and it has successfully obtained patents in the USA, Europe, and Japan.
Unveiled during a recent announcement, the oral formulation aims to enhance treatment options for APL, a blood cancer associated with a high fatality rate. The research team has translated this innovative product into clinical practice after more than 20 years of dedicated work, demonstrating its efficacy and safety through extensive clinical studies. The findings reveal that the oral formulation achieves a remarkable overall survival rate exceeding 97% while significantly reducing side effects.
The establishment of the oral arsenic trioxide represents a new era in cross-border medical collaboration, marking a pivotal development in Hong Kong's healthcare sector. This initiative also aligns with China's national goals to enhance integrated healthcare services. The laboratory aims to promote the flow and application of cross-border medical data, facilitating international cooperation in the field.
The research, made possible by a partnership involving notable institutions, emphasizes the critical nature of knowledge transfer and practical application. By combining engineering innovations with medical science, these collaborative efforts seek to optimize healthcare delivery and develop advanced technologies.
Dr. Harinder Gill, the leading investigator of the study, expressed pride in the impactful translation of their research into practice. He emphasized that the development of ARSENOL® could revolutionize treatment for APL patients, offering a convenient and effective option that significantly improves quality of life. The commitment to ensuring accessibility for all APL patients reflects a dedication to making APL a curable disease globally.
This innovative venture showcases the potential of Hong Kong as a hub for medical advancements and highlights the importance of international collaboration in addressing health challenges. The HKUMed team’s work is not only a testament to their perseverance but also a hopeful sign for the future of cancer treatment.
If you have any needs or questions, please send them to
support@greaterbayhealthcare.com and a dedicated team member will contact you shortly.